Plasmatico: Non-Thermal Plasma in the Fight Against Mpox

Plasmatico, an innovative non-thermal plasma (NTP) sterilization device, has shown significant potential in combating the monkeypox virus (MpoxV). Recent tests conducted at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague demonstrated its effectiveness in reducing viral loads on contaminated surfaces. While alternative methods exist, Plasmatico represents one of the most advanced and efficient approaches to date, particularly for sterilizing delicate materials.

Mpox (formerly known as monkeypox), a viral disease caused by the Orthopoxvirus genus, continues to challenge public health systems worldwide. With a rapid spread across continents and significant outbreaks in Europe, the Americas, and Africa, finding effective and innovative tools for virus inactivation has become critical. Plasmatico, a device generating non-thermal plasma, offers a modern approach to addressing these challenges, especially in the realm of sensitive surfaces and environments.

Innovation in Virus Inactivation

Plasmatico uses advanced non-thermal plasma technology, providing a unique alternative to conventional chemical and heat-based disinfection methods. Its ability to safely and efficiently deactivate viral particles on heat-sensitive and chemically delicate surfaces, such as optical lenses, plastics, delicate electronics, and other critical materials, sets it apart from existing technologies.

Laboratory tests conducted in collaboration with the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague demonstrated the virucidal potential of Plasmatico against the mpox virus (MPXV). While a 10-minute exposure showed limited effectiveness, extending the duration to 60 minutes resulted in a 99.97% reduction in viral titers across both human and monkey cell lines. 90-minute exposure would result in total decontamination.

Global Trends in Mpox: A Persistent Threat

The ongoing mpox outbreak, spanning from 2022 to 2024, has reached an unprecedented scale. According to World Health Organization (WHO) data, 127 countries have reported laboratory-confirmed cases, totaling 117,663 infections and 263 deaths. Among the hardest-hit nations are the United States (over 34,000 cases) and Brazil (over 13,000 cases), highlighting the global reach of the epidemic. Europe has also experienced significant outbreaks, with Spain, France, and Germany contributing to 28,682 cases in the region.

Regional Trends

The African Region remains a hotspot, with 15,267 laboratory-confirmed cases and 77 deaths. The Democratic Republic of the Congo (DRC) leads this region, accounting for 71% of its total cases with over 10,000 infections. Neighboring countries, such as Burundi and Uganda, have also reported substantial case counts.

In the Americas, while overall cases have recently declined by 65%, the United States and Brazil remain centers of concern, contributing significantly to the global totals. The European Region, by contrast, noted a 21% increase in monthly cases as of November 2024, signaling ongoing transmission risks.

Clade Distribution

Africa has predominantly reported cases linked to Clade Ia and Ib, with Clade Ib showing sustained human-to-human transmission, particularly in eastern DRC. Meanwhile, the global outbreak has been primarily driven by Clade IIb, which continues to circulate in Europe and the Americas, disproportionately affecting men who have sex with men (MSM).

Plasmatico’s Role in Public Health

Amid these troubling statistics, Plasmatico represents a much-needed innovation. Unlike traditional methods relying on chemicals or heat, Plasmatico’s non-thermal plasma is highly effective in environments where such methods may damage sensitive surfaces or equipment. Its capability to achieve near-complete virus inactivation within manageable timeframes is a testament to the potential of plasma technology as a powerful disinfection tool.

However, Plasmatico is not the only solution available. Alternative methods, such as advanced UV light systems and specific chemical treatments, also play a role in combating viral transmission. Yet, Plasmatico stands out due to its versatility and suitability for challenging applications, making it a key component in the fight against mpox and other emerging infectious diseases.

The Path Forward

While mpox remains a global health threat, tools like Plasmatico provide a glimpse of hope. By addressing disinfection challenges in specialized environments and delivering scientifically validated results, this innovative technology strengthens the global response against viral outbreaks. As public health systems and researchers continue to collaborate, integrating cutting-edge solutions like Plasmatico could help mitigate the impact of future epidemics.